Randomized controlled phase II trial of glatiramer acetate in ALS

P. H. Gordon, C. Doorish, J. Montes, R. L. Mosely, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, H. E. Gendelman, S. Przedborski, H. Mitsumoto

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

The authors conducted a randomized controlled trial to test the safety and immunology of glatiramer acetate in ALS. Twenty treated patients were randomly assigned to daily or biweekly injections. Ten control patients were selected from another trial and followed up concurrently. Injection reactions were the only common adverse event (p = 0.01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy.

Original languageEnglish (US)
Pages (from-to)1117-1119
Number of pages3
JournalNeurology
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Randomized controlled phase II trial of glatiramer acetate in ALS'. Together they form a unique fingerprint.

  • Cite this

    Gordon, P. H., Doorish, C., Montes, J., Mosely, R. L., Diamond, B., MacArthur, R. B., Weimer, L. H., Kaufmann, P., Hays, A. P., Rowland, L. P., Gendelman, H. E., Przedborski, S., & Mitsumoto, H. (2006). Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology, 66(7), 1117-1119. https://doi.org/10.1212/01.wnl.0000204235.81272.e2